Table AD5

Study 212

Mean (X) and Mean Change (∆) from HAMD Depressed Mood Item #1

LAST OBSERVATION CARRIED FORWARD ANALYSIS

 

Treatment Groups

Treatment Week

Baseline

Wk 1

Wk 2

Wk 3

Wk 4

Wk 5

Wk 6

Wk 7

Wk 8

N

X

N

N

N

N

N

N

N

N

BUP SR 150 (L)

146

2.8

145

-0.4

146

-0.7

146

-0.9

146

-1.0

146

-1.2

146

-1.3

146

-1.3

146

-1.4

BUP SR 300 (II)

144

2.8

144

-0.3

144

-0.5

144

-0.9

144

-1.1

144

-1.1

144

-1.1

144

-1.3

144

-1.3

Placebo (P)

148

2.9

145

-0.3

148

-.06

148

-0.9

148

-1.0

148

-1.1

148

-1.1

148

-1.1

148

-1.1

2-sided p-values for pairwise comparisons

L vs P

> 0.6

0.46

0.48

0.61

0.59

0.50

0.14

0.07

0.10

II vs P

> 0.4

0.57

0.28

0.99

0.12

0.98

0.53

0.26

0.29

OBSERVED CASES ANALYSIS

 

Treatment Groups

Treatment Week

Baseline

Wk 1

Wk 2

Wk 3

Wk 4

Wk 5

Wk 6

Wk 7

Wk 8

N

X

N

N

N

N

N

N

N

N

BUP SR 150 (L)

146

2.8

145

-0.4

136

-0.7

133

-1.0

133

-1.1

122

-1.3

118

-1.4

117

-1.5

110

-1.6

BUP SR 300 (II)

144

2.8

144

-0.3

136

-0.5

131

-1.0

121

-1.3

111

-1.3

104

-1.2

104

-1.5

101

-1.6

Placebo (P)

148

2.9

145

-0.3

140

-0.6

132

-0.9

124

-1.0

117

-1.2

114

-1.3

107

-1.3

100

-1.4

2-sided p-values for pairwise comparisons

L vs P

> 0.6

0.46

0.46

0.70

0.80

0.66

0.37

0.23

0.21

II vs P

> 0.4

0.57

0.32

0.62

0.03

0.71

0.65

0.12

0.14

 

Bupropion SR Clinical Review Addendum for Protocol 212                          19

 

Back a Page
Next Page
Back to Wellbutrin SRŪ NDA Index Page
Back to Main Index

Hosted by www.Geocities.ws

1